Lateral Pharma
Privately funded biotechnology company (Melbourne, Australia) focused on discovery and development of peptide-derived therapeutics that modulate a host-protective biological pathway. Development priorities include a lead peptide-derived clinical candidate being advanced to early-phase trials for neuropathic pain and a preclinical portfolio targeting infectious and inflammatory respiratory diseases. Operations include target identification, in vivo efficacy testing, preclinical screening and preparation for Phase 1/2 clinical proof-of-concept studies.
Industries
Nr. of Employees
small (1-50)
Products
Lead peptide-derived clinical candidate (previously clinically tested)
A peptide-derived small-molecule candidate with prior human safety data from Phase II development, being developed for neuropathic pain and considered for respiratory disease indications.
Lead peptide-derived clinical candidate (previously clinically tested)
A peptide-derived small-molecule candidate with prior human safety data from Phase II development, being developed for neuropathic pain and considered for respiratory disease indications.
Services
Discovery, design and preclinical screening of peptide-derived candidates and lower molecular weight derivatives for neuropathic pain and respiratory disease indications.
Design and conduct of Phase 1/2 clinical proof-of-concept studies for lead candidates, including IV administration approaches and safety monitoring.
Discovery, design and preclinical screening of peptide-derived candidates and lower molecular weight derivatives for neuropathic pain and respiratory disease indications.
Design and conduct of Phase 1/2 clinical proof-of-concept studies for lead candidates, including IV administration approaches and safety monitoring.
Expertise Areas
- Peptide therapeutic discovery
- Preclinical in vivo pharmacology
- Neuropathic pain drug development
- Respiratory infectious and inflammatory disease therapeutics
Key Technologies
- Peptide therapeutics
- In vivo disease models (neuropathic pain, respiratory infection)
- Preclinical screening platforms
- Early-phase clinical trial methodologies
News & Updates
Announcement regarding completion of a proof-of-concept clinical trial for the lead clinical candidate.
Publication announcement related to controlling inflammation in lung infections.
Preclinical results presented at AD/PD 2025 showing effects on neuronal viability and amyloid deposition.
Investor/external briefing document summarizing company activities.
Announcement regarding completion of a proof-of-concept clinical trial for the lead clinical candidate.
Publication announcement related to controlling inflammation in lung infections.
Preclinical results presented at AD/PD 2025 showing effects on neuronal viability and amyloid deposition.
Investor/external briefing document summarizing company activities.